Dec 23, 2025 08:06AM Agenus publishes ovarian cancer treatment results in medical journal

Nov 18, 2025 08:41AM Agenus names José Iglesias chief medical affairs officer

Oct 20, 2025 06:57AM H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN)

Sep 10, 2025 07:32AM H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN)

Sep 9, 2025 07:45AM AGENUS gets french compassionate access for cancer drug combination

Aug 19, 2025 07:30AM Agenus plans virtual briefing on cancer drug developments Aug. 27

Aug 12, 2025 06:07AM Agenus Inc. (AGEN) PT Lowered to $23 at H.C. Wainwright

Aug 11, 2025 10:56AM Agenus (AGEN) Misses Q2 EPS by 100c

Jul 25, 2025 12:46PM Agenus to present cancer drug data at ESMO 2025 conference

Jul 11, 2025 10:46AM Agenus (AGEN) Trades Higher in Sympathy with MiNK Therapeutics (INKT)

Jul 8, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN)

Jul 7, 2025 08:56AM Agenus drug combo shows 42% two-year survival in colorectal cancer trial

Jun 17, 2025 07:31AM Agenus (AGEN) and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 4, 2025 06:04AM H.C. Wainwright Upgrades Agenus Inc. (AGEN) to Buy

Jun 3, 2025 08:01AM Agenus (AGEN) to Sell U.S. manufacturing facilities to Zydus Lifesciences

Jun 3, 2025 07:05AM Agenus (AGEN) and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

May 13, 2025 06:23AM Agenus (AGEN) Misses Q1 EPS by 103c

May 12, 2025 07:21AM Agenus (AGEN) Appoints Richard Goldberg as Chief Development Officer

Mar 18, 2025 06:45AM H.C. Wainwright Reiterates Neutral Rating on Agenus Inc. (AGEN)

Mar 11, 2025 04:50PM Agenus (AGEN) Misses Q4 EPS by 204c

Feb 4, 2025 10:39AM Kuehn Law Encourages Investors of Agenus Inc. to Contact Law Firm

Jan 29, 2025 12:37PM Agenus (AGEN) Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 22, 2025 02:49PM Agenus (AGEN) Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Dec 5, 2024 07:31AM Agenus (AGEN) Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Nov 29, 2024 06:34AM H.C. Wainwright Reiterates Neutral Rating on Agenus Inc. (AGEN)

Nov 27, 2024 08:15AM Agenus (AGEN) Secures $22M Mortgage and Announces Strategic Operational Realignment

Nov 13, 2024 06:55AM Agenus Inc. (AGEN) PT Lowered to $7 at H.C. Wainwright

Sep 18, 2024 07:00AM GSK (GSK) Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

Sep 13, 2024 10:01AM Agenus (AGEN) Presents Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas

Aug 14, 2024 07:44AM Agenus Inc. (AGEN) PT Lowered to $18 at B.Riley

Aug 8, 2024 07:24AM Agenus (AGEN) Misses Q2 EPS by 64c

Aug 8, 2024 07:01AM Agenus (AGEN) Appoints Tom Harrison to its Board

Aug 2, 2024 04:07PM Agenus (AGEN): BMS is returning AGEN1777 back to Agenus

Jul 19, 2024 08:55AM Jefferies Downgrades Agenus Inc. (AGEN) to Hold

Jul 19, 2024 07:20AM William Blair Downgrades Agenus Inc. (AGEN) to Market Perform

Jul 19, 2024 02:41AM Baird Downgrades Agenus Inc. (AGEN) to Neutral

Jul 18, 2024 12:34PM H.C. Wainwright Downgrades Agenus Inc. (AGEN) to Neutral

Jul 18, 2024 11:10AM Increasing unusual call option volume: VIRT AUR AGEN ITB APTV KOPN LPSN

Jul 18, 2024 07:37AM Agenus (AGEN) Falls 32% After Announcing End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

Jul 18, 2024 07:35AM Agenus (AGEN) Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

Jul 1, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN)

Jun 17, 2024 07:01AM Agenus (AGEN) Appoints Jennifer Buell to its Board